Chlamydia Infection Diagnostics Market Report 2026

Chlamydia Infection Diagnostics Market Overview

• Chlamydia Infection Diagnostics market size has reached to $1.4 billion in 2025 • Expected to grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Preventive Healthcare Boosts Growth of Chlamydia Diagnostics Market • Market Trend: Chlamydia Diagnostics Market Advances With Molecular Point Of Care Testing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chlamydia Infection Diagnostics Market?

Chlamydia infection diagnostics refers to the methods and procedures used to identify and confirm the presence of Chlamydia trachomatis bacteria in individuals suspected of having a chlamydial infection. Diagnostic tests are crucial for accurate diagnosis, treatment planning, and prevention of further transmission. The main test types of chlamydia infection diagnostics are culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, and others. A culture test typically refers to a diagnostic procedure where samples from a patient are cultured to detect the presence of microorganisms, helping diagnose infections or identify the appropriate treatment. It is done in different types of infections, including genital chlamydia infection, rectal chlamydia infection, and ocular chlamydia infection. The applications are in hospitals, specialty clinics, and diagnostic centers, and they are used by various end users, such as diagnostics and therapeutics.

What Is The Chlamydia Infection Diagnostics Market Growth Forecast?

The chlamydia infection diagnostics market size is expected to see rapid growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing demand for rapid and automated diagnostics, rising investments in laboratory automation, expansion of decentralized diagnostic testing, growing focus on early infection detection, continuous innovation in molecular testing technologies. Major trends in the forecast period include increasing deployment of advanced molecular diagnostic platforms, rising adoption of pcr and lamp-based tests, growing integration of automation in diagnostic laboratories, expansion of high-throughput screening capabilities, enhanced focus on diagnostic accuracy and speed.

Global Chlamydia Infection Diagnostics Market Segmentation

1) By Test Type: Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test, Other Test Types 2) By Type Of Infections: Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection 3) By Application: Hospitals, Specialty Clinics, Diagnostic Centers 4) By End User: Diagnostics, Therapeutics Subsegments: 1) By Culture Test: Cell Culture, Egg Culture 2) By Nucleic Acid Amplification Test (NAAT): PCR-Based Test, LAMP-Based Test 3) By Direct Fluorescent Antibody Test: Direct Fluorescent Antibody Staining, Direct Fluorescent In-Situ Hybridization 4) By Serology Test: Immunoassays, Enzyme Immunoassay (EIA) 5) By Other Test Types: Enzyme-Linked Immunosorbent Assay (ELISA), Hybrid Capture Test

What Is The Driver Of The Chlamydia Infection Diagnostics Market?

The growing focus on preventive healthcare is expected to propel the chlamydia infection diagnostics market going forward. Preventive healthcare involves measures taken to prevent diseases, rather than treating them after they occur, through regular check-ups, vaccinations, and lifestyle modifications. The growing focus on preventive healthcare aims to reduce healthcare costs, improve quality of life, and prevent the onset of chronic diseases through early detection and proactive health measures. Preventive healthcare plays a crucial role in chlamydia diagnostics by emphasizing early detection, education, and routine screening, which collectively help in reducing the spread and complications of chlamydia infections. For instance, in May 2023, according to the National Health Service (NHS), a UK-based publicly funded healthcare system, around 23.02 million diagnostic tests were conducted in March 2023, reflecting an increase of 223,100 tests compared to March 2022. Further, in March 2023, the number of patients waiting for a critical diagnostic test reached 16.28 million, marking an increase of 59,400 compared to March 2022. Therefore, the growing focus on preventive healthcare drives the growth of the chlamydia infection diagnostics industry.

Key Players In The Global Chlamydia Infection Diagnostics Market

Major companies operating in the chlamydia infection diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Cepheid, Meridian Bioscience Inc., Sekisui Diagnostics, Copan Diagnostics

Global Chlamydia Infection Diagnostics Market Trends and Insights

Major companies operating in the chlamydia infection diagnostic market focus on developing advanced products, such as molecular point-of-care testing platforms, to gain a competitive edge. Molecular point-of-care (POC) testing platforms are diagnostic tools designed to detect and analyze specific nucleic acids (DNA or RNA) of pathogens directly at the patient care site. For instance, in May 2024, Sherlock Biosciences, a US based biotech company, announced development of Sherlock test which is one of the first molecular disposable tests for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG). The diagnostic test results are provided in under 30-minutes by analyzing DNA and RNA self-collected through penile meatal or vaginal swabs.

What Are Latest Mergers And Acquisitions In The Chlamydia Infection Diagnostics Market?

In December 2023, Imaware, a US-based digital health company, acquired the consumer testing business of Binx Health for an undisclosed amount. With this acquisition, Imaware aims to strengthen its position as a leader in STI health screening, expand its consumer testing offerings, enhance access to at-home diagnostic solutions, and accelerate growth in the sexual health market. Binx Health is a US-based healthcare company that provides at-home testing solutions for sexually transmitted infections (STIs).

Regional Outlook

North America was the largest region in the chlamydia infection diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chlamydia Infection Diagnostics Market?

The chlamydia infection diagnostics market includes revenues earned by entities by providing services such as laboratory testing services, point-of-care testing, and consultation and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chlamydia Infection Diagnostics Market Report 2026?

The chlamydia infection diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.